Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 1 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 1 | 360 aa | 361 aa | 33.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0062 | 0.4044 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.4044 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0062 | 0.4044 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.4044 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.4044 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0062 | 0.4044 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.4044 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0062 | 0.4044 | 1 |
Brugia malayi | MAP kinase sur-1 | 0.0062 | 0.4044 | 0.4044 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0062 | 0.4044 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0.4044 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0062 | 0.4044 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0062 | 0.4044 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0.4044 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0062 | 0.4044 | 0.4044 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0062 | 0.4044 | 1 |
Brugia malayi | Smad1 | 0.001 | 0.0316 | 0.0316 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0062 | 0.4044 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0062 | 0.4044 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0062 | 0.4044 | 0.5 |
Loa Loa (eye worm) | Smad1 | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Trypanosoma brucei | protein kinase, putative | 0.0062 | 0.4044 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0062 | 0.4044 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.1 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.122 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.